Abstract: This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.

Abstract: This application relates to pharmaceutical compositions, comprising solabegron that are useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to methods for treating lower urinary tract symptoms utilizing the pharmaceutical compositions, comprising solabegron. In some embodiments, the pharmaceutical compositions, comprising solabegron comprise a dual release drug delivery system.

Abstract: In various examples, a system comprises a rack-mountable power distribution unit (PDU). The PDU may: receive an alternating current (AC) power feed, convert the AC to a direct current (DC) power pool, determine an amount of available amount of power of the DC power pool to be delivered to devices electrically coupled to the PDU, and output the DC power pool to the devices coupled to the PDU based on the amount of available power.

Abstract: This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.

Abstract: The present invention relates in certain embodiments to a controlled release formulation, especially a sachet, comprising a unit dosage of a dry powder of tamsulosin or a pharmaceutically acceptable salt thereof in a controlled release matrix and to methods of making and using such formulation. The controlled release formulation is beneficial in the treatment of benign prostatic hyperplasia (BPH), particularly in those patients suffering from dysphagia. The controlled release formulation is easily dispersed in water or other suitable liquid, and so solves the problem of dysphagia, thereby improving patient compliance in that targeted patient population, yet the controlled release formulation has a release profile in a patient on an empty stomach similar to FLOMAX® ((R)-5-(2-{[2-(2-Ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzene-1-sulfonamide hydrochloride) taken 30 minutes after a meal, but does not exhibit the FLOMAX® tablet food effect, thereby improving dosage form administration flexibility.

Abstract: A method of preparing specimens for peel-adhesion testing. The method includes applying a first predetermined amount of light-curable material to a substrate coupon, placing a first surface of a substantially transparent peel media in contact with the light-curable material disposed on the substrate coupon, where the substantially transparent peel media includes a second surface spaced from the first surface, and exposing the first predetermined amount of light-curable material disposed between the substrate coupon and the first surface to a light source to cure the first predetermined amount of light-curable material, with light from the light source passing through the substantially transparent peel media to the substrate coupon.

Abstract: This application relates to pharmaceutical compositions, comprising solabegron that are useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to methods for treating lower urinary tract symptoms utilizing the pharmaceutical compositions, comprising solabegron. In some embodiments, the pharmaceutical compositions, comprising solabegron comprise a dual release drug delivery system.

Abstract: This application relates to pharmaceutical compositions, comprising solabegron that are useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to methods for treating lower urinary tract symptoms utilizing the pharmaceutical compositions, comprising solabegron. In some embodiments, the pharmaceutical compositions, comprising solabegron comprise a dual release drug delivery system.

Abstract: This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.

Abstract: Examples described herein relate to power distribution units (PDUs) with receptacles on one surface and branch rated circuit protection devices on an opposite surface. For example, a PDU includes a first surface including a plurality of receptacles to couple a plurality of electronic devices to the PDU. The PDU also includes a second surface, opposite the first surface, including a plurality of branch rated circuit protection devices associated with the plurality of receptacles.

Abstract: Examples described herein relate to circuit breaker assemblies with changeable orientation. In one example, an apparatus includes a circuit breaker assembly and a circuit breaker housing to receive the circuit breaker assembly. The circuit breaker assembly includes a circuit breaker including a contact, a cover plate attached to a surface of the circuit breaker, and a handle movable between a first position and a second position. The circuit breaker assembly is removably attachable to the circuit breaker housing to change an orientation of the circuit breaker assembly.

Abstract: This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.

Abstract: The present application is directed to polysulfide sealant formulations, application of such sealants, and methods for reducing the density of polysulfide sealant formulations.

Abstract: A method of preparing specimens for peel-adhesion testing.

Abstract: Examples herein relate to a cable bracket for a datacenter rack, the cable bracket includes a plurality of retention clamps, each retention clamp adapted to retain a cable and a side plate longitudinally connected to the plurality of retention clamps, the side plate includes mechanical attachment features. The side plate of the cable bracket is adapted to be directly attached by the mechanical attachment features on a rail of the datacenter rack and the cable bracket is located between the rail and a side panel of the datacenter rack.

Abstract: The present invention relates to systems and methods for preparing reactively sputtered films. The films are generally thin transition metal oxide (TMO) films having an optimum stoichiometry for any useful device (e.g., a sub-stoichiometric thin film for a memristor device). Described herein are systems, methods, and calibrations processes that employ rapid control of partial pressures to obtain the desired film.

Abstract: This application relates to solabegron zwitterion useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to pharmaceutical compositions and methods of treatment utilizing the solabegron zwitterion for treating lower urinary tract symptoms. This application also relates to methods of preparing solabegron hydrochloride from the solabegron zwitterion.

Abstract: Example implementations relate to power delivery monitor and control with an uninterruptible power supply (UPS). For example, a UPS includes a power output receptacle to supply power to a power extension bar coupled to the UPS via a power cable, the extension bar to provide the power to a plurality of computing devices coupled to the extension bar. The UPS also includes a data communication port to couple the UPS to the extension bar via a communication cable, and a controller module to monitor and control power delivered to a plurality of power output receptacles on the extension bar.

Abstract: An example device in accordance with an aspect of the present disclosure includes a housing, mountable to a power distribution unit (PDU) associated with at least one circuit breaker. The device also includes a mechanism coupled to the housing, movable between a first position and a second position to reset the at least one circuit breaker, in response to receiving a reset signal.

Abstract: Examples described herein relate to circuit breaker assemblies with changeable orientation. In one example, an apparatus includes a circuit breaker assembly and a circuit breaker housing to receive the circuit breaker assembly. The circuit breaker assembly includes a circuit breaker including a contact, a cover plate attached to a surface of the circuit breaker, and a handle movable between a first position and a second position. The circuit breaker assembly is removably attachable to the circuit breaker housing to change an orientation of the circuit breaker assembly.